CAS 1262133-66-3
:2'-O-(5'-Deoxy-beta-D-ribofuranosyl) Capecitabine
Description:
2'-O-(5'-Deoxy-beta-D-ribofuranosyl) Capecitabine is a nucleoside analog and a prodrug of the chemotherapeutic agent capecitabine, which is primarily used in the treatment of various cancers, including breast and colorectal cancer. This compound features a ribofuranosyl sugar moiety, which is modified at the 2' position, enhancing its stability and bioavailability. The presence of the 5'-deoxy modification contributes to its pharmacological properties, allowing for selective activation in tumor tissues. The mechanism of action involves the conversion to 5-fluorouracil (5-FU) in the body, which interferes with DNA synthesis and ultimately inhibits cancer cell proliferation. The compound is characterized by its relatively low toxicity to normal cells compared to traditional chemotherapeutics, making it a valuable option in cancer therapy. Its chemical structure includes specific functional groups that facilitate its interaction with enzymes involved in nucleotide metabolism. Overall, 2'-O-(5'-Deoxy-beta-D-ribofuranosyl) Capecitabine exemplifies the advancements in targeted cancer treatment through the design of prodrugs that enhance therapeutic efficacy while minimizing side effects.
Formula:C20H30FN3O9
Synonyms:- 5'-Deoxy-2'-O-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
- [1-[5'-Deoxy-2-O-(5'-deoxy-β-D-ribofuranosyl)-β-D-ribofuranosyl]-5-fluoro-2-oxo-1,2-dihydropyriMidin-4-yl]carbaMic Acid Pentyl Ester
- 2'-O-(5'-Deoxy-β-D-ribofuranosyl) Capecitabine
- 2'-(5'-Deoxy-Beta-D-ribofuranoyl) Capecitabine
- Capecitabine impurity 2/Capecitabine USP Impurity H/Capecitabine 2-O-BDR Impurity
- 2’-O-(5’-Deoxy-β-D-ribofuranosyl) Capecitabine
- Capecitabine 2-O-BDR Impurity (USP)
- Capecitabine-related impurities G
- 2'-O-(5'-Deoxy-beta-D-ribofuranosyl) Capecitabine
- [1-[5'-Deoxy-2-O-(5'-deoxy-β-D-ribofuranosyl)-β-D-ribofuranosyl] -5-fluoro-2-oxo-1,2-dihydropyriMidin-4-yl] carbamic acid pentyl ester
- Capecitabine USP Impurity H
- Capecitabine 2-O-BDR Imp
- Capecitabin iMpurity H
- Capecitabine Impurity H(USP)
- Capecitabine Related Compound H
- Cytidine, 5'-deoxy-2'-O-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-N-[(pentyloxy)carbonyl]-
- Capecitabine impurity 2/Capecitabine USP Impurity H/Capecitabine 2-O-BDR Impurity/2’-O-(5’-Deoxy-β-D-ribofuranosyl) Capecitabine
- Capecitabine USP IMp.H
- 2'-O-(5'-Deoxy-2,3-diacetyl-β-D-ribofuranosyl) Capecitabine 3-Benzoate
- Capecitabine 2-O-DR Impurity
- Capecitabine Impurity L
- Capecitabine-6
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 7 products.
2'-O-(5-deoxy-β-D-ribofuranosyl) Capecitabine ([1-[5-Deoxy-2-O-(5-deoxy-β-D-ribofuranosyl)-β-D-ribofuranosyl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]-carbamic acid pentyl ester)
CAS:<p>Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoi</p>Formula:C20H30FN3O9Color and Shape:Off-White Light Green SolidMolecular weight:475.196612’-O-(5’-Deoxy-b-D-ribofuranosyl) Capecitabine
CAS:Formula:C20H30FN3O9Purity:95%Color and Shape:SolidMolecular weight:475.4653Capecitabine Impurity 39
CAS:Formula:C20H30FN3O9Color and Shape:Off-White SolidMolecular weight:475.482’-O-(5’-Deoxy-β-D-ribofuranosyl) Capecitabine-d11
CAS:Controlled Product<p>Applications Labelled Capecitabine (C175650) impurity.<br></p>Formula:C20D11H19FN3O9Color and Shape:NeatMolecular weight:486.5332’-O-(5’-Deoxy-β-D-ribofuranosyl) Capecitabine
CAS:Controlled Product<p>Impurity Capecitabine 2-O-BDR Impurity (USP)<br>Stability Hygroscopic<br>Applications Capecitabine (C175650) impurity. Capecitabine 2-O-BDR Impurity (USP).<br></p>Formula:C20H30FN3O9Color and Shape:NeatMolecular weight:475.472™-O-(5™-Deoxy-²-D-ribofuranosyl) Capecitabine-d11
CAS:<p>Please enquire for more information about 2™-O-(5™-Deoxy-²-D-ribofuranosyl) Capecitabine-d11 including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>Formula:C20H19D11FN3O9Purity:Min. 95%Molecular weight:486.53 g/mol






